Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future medicines to market.

German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing foreign-exchange effects and uncertainty over tariffs.

Merck, known as MSD outside of the United States and Canada, announced the start of construction for a $1 billion, 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, ...

Governor of Delaware, in the press release. “Merck is pioneering the next generation of care right here in Wilmington, and they couldn’t have picked a better place to do it. The positive impact this ...

Officially called Merck Wilmington Biotech ... which earlier this year received a $30.2-million grant from Delaware’s Council of Development Finance. The company’s presentation to the agency ...

In the latest instalment of a long-running dispute, the Court of Appeal has recently upheld the High Court judge's view on ...

Germany’s Merck KGaA (MRK: DE) today announced the presentation of detailed positive results from Part 1 of the global Phase ...

First, it was Panasonic. Now, another major company is planting deeper roots in De Soto. Merck Animal Health has announced an expansion of its De Soto operations, and it’s bringing hundreds of ...